- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00937898
Beef in an Optimal Lean Diet (BOLD) Effects on Cardiovascular Disease (CVD) Risk (BOLD)
August 16, 2023 updated by: Penn State University
BOLD (Beef in an Optimal Lean Diet) Effects on Established and Emerging Cardiovascular Disease (CVD) Risk Factors
The study is designed to assess the effects of a heart-healthy diet that includes lean beef as the primary source of high quality protein on risk factors for cardiovascular disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- BMI > 20 and < 37
- LDL-C level between the 50th and 90th percentile (±5% for assay variation) according to NHANES data for sex and age (ex. for men: 128-177 mg/dL and for women: 121-172 mg/dL)
- TG level < 150 mg/dL
Exclusion criteria include:
- self-reported history of myocardial infarction, stroke, diabetes mellitus, liver disease, kidney disease, and thyroid disease (unless controlled on medication)
- high alcohol consumption (≥ 14 drinks/week)
- intake of putative cholesterol-lowering supplements (psyllium, fish oil capsules, soy lecithin, niacin, fiber, flax, and phytoestrogens, stanol/sterol supplemented foods)
- treatment with lipid-lowering agents (statins and fibrates) or blood pressure control medications
- vegetarian diet
- weight loss or gain ≥ 10% body weight in the previous 6 months,
- lactation, pregnancy, or desire to become pregnant during the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DASH Diet
High fruit and vegetable, low sodium diet
|
Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
|
Active Comparator: Average American Diet
Typical American diet (16% protein, ~50% carbohydrate, 33% fat)
|
Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Lipids (Total cholesterol, LDL-C, HDL-C, TG)
Time Frame: End of each 5 week diet period (weeks 5, 11, 17, 23)
|
End of each 5 week diet period (weeks 5, 11, 17, 23)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Apolipoprotein levels
Time Frame: End of each 5 week diet period (weeks 5, 11, 17, 23)
|
End of each 5 week diet period (weeks 5, 11, 17, 23)
|
Vascular function
Time Frame: End of each 5 week diet period (weeks 5, 11, 17, 23)
|
End of each 5 week diet period (weeks 5, 11, 17, 23)
|
Oxidative Stress
Time Frame: End of each 5 week diet period (weeks 5, 11, 17, 23)
|
End of each 5 week diet period (weeks 5, 11, 17, 23)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Penny M Kris-Etherton, PhD, Penn State University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2007
Primary Completion (Actual)
August 1, 2011
Study Completion (Actual)
March 1, 2012
Study Registration Dates
First Submitted
June 18, 2009
First Submitted That Met QC Criteria
July 10, 2009
First Posted (Estimated)
July 13, 2009
Study Record Updates
Last Update Posted (Actual)
August 21, 2023
Last Update Submitted That Met QC Criteria
August 16, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PKE101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolemia
-
National Medical Research Center for Therapy and...Moscow State University of Medicine and DentistryRecruitingMedication Adherence | Adherence, Medication | Treatment Adherence | Familial Hypercholesterolemia | Motivational Interviewing | Adherence, Patient | Treatment Adherence and Compliance | Patient Compliance | Adherence | Hypercholesterolemia, Familial | Patient Adherence | Hypercholesterolemia, Autosomal Dominant and other conditionsRussian Federation
-
Direct PlantesUnknownHYPERCHOLESTEROLEMIAFrance
-
Chong Kun Dang PharmaceuticalRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Provident Clinical ResearchGlaxoSmithKlineCompletedPrimary HypercholesterolemiaUnited States
-
Addpharma Inc.CompletedPrimary HypercholesterolemiaKorea, Republic of
-
JW PharmaceuticalCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Organon and CoCompletedPrimary Hypercholesterolemia | Homozygous Familial Hypercholesterolemia
-
Boryung Pharmaceutical Co., LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
-
Ahn-Gook Pharmaceuticals Co.,LtdRecruitingPrimary HypercholesterolemiaKorea, Republic of
Clinical Trials on BOLD+ Diet
-
Penn State UniversityNational Cattlemen's Beef AssociationCompletedCardiovascular Disease | Metabolic SyndromeUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedIntrauterine Growth RestrictionFrance
-
Samsung Medical CenterNational Research Foundation of KoreaUnknown
-
Zimmer BiometCompletedPeripheral Arterial Disease | Critical Limb IschemiaUnited States
-
University Hospital Inselspital, BerneActive, not recruitingKidney Transplantation | Urinary CalculiSwitzerland
-
National Institute on Aging (NIA)Completed
-
General Hospital of Ningxia Medical UniversityUnknownCharacterize and Evaluate Functional After Transplantation | Determine the Therapeutic Efficiency | Correlate the Imaging ResultsChina
-
Ontario Clinical Oncology Group (OCOG)Completed
-
Washington University School of MedicineCompletedNeural ConnectivityUnited States